OncoMatch/Clinical Trials/NCT06778408
Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial
Is NCT06778408 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for palliative radiotherapy.
This is a prospective single-center single-arm Phase II trial of HART for patients with metastatic cancer. The primary objective is to assess the incidence of acute GI toxicity following HART. PRO-CTCAE GI scores observed in the study patients will be compared to historical rates. Secondary outcomes include measuring changes in health-related quality of life, esophageal quality of life, toxicity, dosimetric outcomes, and pain.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: cytotoxic chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Vermont Medical Center · Burlington, Vermont
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify